Krystal Biotech expands oncology research following FDA acceptance of investigational drug application

Krystal Biotech Inc. announced that its KB707 drug candidate can begin being used for the treatment of locally advanced or metastatic solid tumor malignancies in select patients who have solid tumors that are accessible via injection.